Funding update (March 2026)
The next frontier of precision diagnostics: glycoproteomics.
"Current diagnostics measure the messenger, not the message."
Proseek Bio is an clinical-stage diagnostic company seeking impact investors with health and diagnostics focus to support our ovarian cancer detection test deployment and pipeline extension to other women's health diagnostics and companion diagnostics.
$4B
+
Global addressable market for ovarian mass triage alone
300K
+
Women diagnosed with ovarian masses globally each year
80%
Of surgeries for suspicious ovarian masses are unnecessary
"
A breakthrough with the potential to benefit millions of women worldwide. Their dedication and vision make them a delight to work alongside, and their mission is not only ambitious but truly vital for global women's health.
— Warren Bingham, Executive Chair, Medtech International
THE PROBLEM
Ovarian Cancer diagnosis is broken.
80%
Of women undergoing surgery for suspicious ovarian masses don't actually have cancer.
$20K
+
Cost per unnecessary surgery, creating a
multi-billion dollar global healthcare burden each year.
CA-125
The current standard test is decades-old technology with poor sensitivity and specificity that is not fit for clinical triage.
Stage III to IV
Most ovarian cancers are diagnosed at advanced stages because early detection tools simply don't exist yet.
OC-TRIAGE: a simple blood test that changes everything.
OC-TRIAGE is a glycoproteomic blood test measuring protein and glycan signatures from a standard blood draw, delivering a clear high/low risk result to guide clinical decisions.
HOW IT WORKS
1
Standard blood draw
<0.01ml serum — no new equipment needed
2
Sample processed with Proseek Bio kit
Compatible with existing clinical lab mass spec
3
Mass spectrometry analysis
LC-QQQ MS; existing clinical infrastructure
4
Glycan + protein signals read
Multi-biomarker signature reveals disease activity
5
Actionable clinical report
Clear high/low risk — avoids unnecessary surgery
.png)
OUR SOLUTION
TRACTION AND NEWS
Momentum across funding, programs, and partnerships.
